PRAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Praxis Precision Medicines Inc (PRAX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including bullish analyst ratings, significant institutional buying, and promising FDA-related developments. While financial performance shows challenges, the long-term growth potential in neurology and epilepsy markets outweighs the risks.
The technical indicators are bullish. The MACD is positive and contracting, RSI is neutral at 61.633, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above the pivot level of 327.911, with resistance at 351.973 and support at 303.848. This suggests a positive trend in the short term.
Multiple analysts have raised price targets significantly, with some projecting values as high as $1,
Institutional investors like Baker Bros. Advisors and Perceptive Advisors have significantly increased their stakes in PRAX, reflecting strong confidence.
The company has completed NDA submissions for two key drugs, ulixacaltamide and relutrigine, with FDA reviews expected soon.
The neuroscience biotech sector is gaining traction, and PRAX is positioned as a key player in essential tremor and epilepsy markets.
Financial performance in Q4 2025 shows no revenue and a net loss of $88.91 million, though net income and EPS have improved YoY.
Wells Fargo and Wedbush have expressed concerns about the approval of ulixacaltamide, citing uncertainties and a 50% probability of success.
In Q4 2025, revenue dropped to $0 (-100% YoY), gross margin also dropped to 0, and net income improved to -$88.91 million (+51.52% YoY). EPS increased to -3.49 (+19.11% YoY). While financials show improvement in losses, the lack of revenue is a concern.
Analyst sentiment is overwhelmingly positive, with multiple firms raising price targets. Wolfe Research initiated coverage with an Outperform rating and a $500 price target. H.C. Wainwright has the highest target at $1,245, citing transformative potential in ulixacaltamide and relutrigine. However, Wedbush remains cautious with an Underperform rating and a $130 price target, citing concerns about the ulixacaltamide filing.
